PRM / ViroGates announces initial data on the use of suPARnostic in the triaging of patients with COVID-19 symptoms

BIRKERØD, DENMARK – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that clinical researchers from the US, Greece and Denmark have disclosed the first clinical data on suPAR in patients affected by the novel coronavirus SARS-CoV-2.

Pressemeddelelse fra ViroGates

The groups looked specifically at patients with a positive diagnostic test for the coronavirus and how the clinical symptoms developed over 14 days. About 20-30% of patients with SARS-CoV-2 infection progress to develop severe respiratory failure (SRF). The researchers looked at whether suPAR levels at admission can predict which patients will develop SRF during a follow-up of 14 days from the first presentation. The data showed that patients with a suPAR level above 6ng/ml had a significant (p < 0.0001) 16 times higher risk of developing SRF than those with a suPAR level below 6 ng/ml. The researches also looked at other biomarkers such as CRP and Neutrophils and none of these could predict the development of SRF.

The findings in the letter suggest that suPAR may early trace COVID-19 patients who develop SRF. Early identification of high-risk COVID-19 patients may be useful when deciding to admit or discharge patients to:

Jakob Knudsen, Chief Executive Officer of ViroGates, says: “We are very enthusiastic about these new data. We look forward to seeing data in larger populations and with longer follow up, but these early findings show that suPARnostic® is indeed capable of supporting front line health care personnel in early triaging and identifying patients that need special attention and patients that can be observed in home quarantine or less urgent and resource-demanding environments than an Intensive Care Unit or isolation wards at the hospital.”

The study is published as a Research Letter in the Critical Care Journal and can be found as open access at https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-02897-4

For further information please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com

Læs hele pressemeddelelsen på Via Ritzau her: https://via.ritzau.dk/pressemeddelelse/virogates-announces-initial-data-on-the-use-of-suparnostic-in-the-triaging-of-patients-with-covid-19-symptoms?releaseId=13592685

** Ovenstående pressemeddelelse er videreformidlet af Ritzau på vegne af tredjepart. Ritzau er derfor ikke ansvarlig for indholdet **